Short Sellers Get Selective on Major Pharma

Health and Healthcare

Published: July 27, 2016 8:25 am

Last Updated: January 13, 2020 5:14 am

The short interest data have been released for the July 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be big upside.

Drug prices may be under pressure due to the campaign trail and under scrutiny, but if generic drugs are going to keep increasing in market share of existing drugs then there would seem to be a reason for owning major pharmaceuticals.

The July 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest was mixed.

A reminder: short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.

Pfizer Inc. (NYSE: PFE) saw its short interest decrease to 47.67 million shares from the previous 50.67 million. Shares of Pfizer closed Tuesday at $36.83, within a 52-week trading range of $28.25 to $37.19.

Merck & Co. Inc. (NYSE: MRK) had a rise in short interest to 32.06 million shares from 30.33 million in the previous period. Its shares closed Tuesday at $58.36, in a 52-week range of $45.69 to $60.07.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) short interest increased to 22.34 million shares. The previous level was 19.97 million. Shares closed Tuesday at $54.31, in a 52-week range of $48.01 to $71.78.

Bristol-Myers Squibb Co. (NYSE: BMY) saw its short interest increase to 17.42 million shares from the previous reading of 16.02 million. Shares closed Tuesday at $75.06, within a 52-week range of $51.82 to $77.12.

AbbVie Inc. (NYSE: ABBV) short interest fell to 60.57 million shares, compared to the previous 71.16 million. Shares of AbbVie closed Tuesday at $64.45, in a 52-week trading range of $45.45 to $71.51.

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.